Quipt Home Medical Corp T.QIPT

Buzz on the Bullboards: Updates from Nevada Copper, BlackBerry, Tilray

[Odinson]

There was a news article on this issue earlier today. I don't use that junk so I didn't pay much attention to it. I tried it for a short time and quite frankly, dying from Diabetes is far

[westcoastlogger]

I see a recent study at Harvard has concluded that people prescribed semaglitude were seven times more likely to end up with a form of blindness. Not good in my book for the fatties that won't get

[KarlGibbons]

Now that we all agree that ajd EBITDA is a useless metric for QIPT given its mostly DA, we thereby also must agree that leverage levels may not be modest.  Relative to EBITA, its very high, more

[KarlGibbons]

russell rebalance happening end of June

[HatrikSeLaine]

Do I see that correctly as about 800,000 shares traded hands on the US after market yesterday?   Is it related to quarter end?

[Tropicalsun]

Notice the trading right at close and after market? What does it mean?

[best0be]

Quipt Home Medical Corp. Common Shares (QIPT) Short Interest     Settlement Date Short

[Jonathon Brown]

The past week has been a roller-coaster ride for the TSX. Volatility was the theme as the market saw dramatic rises and falls. read article.

[best0be]

ON BUYBACKS 5/19/24, 11:43 AM

[lscfa]

Stop misleading people. Co. is entering diabetes segment and cross selling CGMs and supplies at no extra cost to SG&A. 

[lscfa]

      ResMed has been tracking the impact of GLP-1s through a de-identified patient analysis using an overlap of our data and third-party claims data. With another quarter of data

[sollmg]

  Despite investors’ concerns over ResMed’s future sales, analysts remain positive. After the shares dipped today, analyst Mathieu Chevrier from Citi reiterated a Buy rating on RMD stock

[sollmg]

Tirzepatide patients also had a 55% to 63% reduction in nighttime sleep apnea events. ResMed, though, notes many patients still had enough events to require a CPAP machine. And William Blair analyst

[KarlGibbons]

You are going down the lscfa rabbit hole of trying to find info/stories to corroborate your long holding despite the market telling you that you've been wrong for many years.  Listen to the

[sollmg]

Both trials were conducted for 52 weeks to compare the baseline number of apnea events (instances in which the patient stopped breathing while sleeping) against the number after 52 weeks. In the

[sollmg]

Given the relatively modest near-term headwind we expect through FY27, we view today’s weakness as a buying opportunity,” they wrote.